214 related articles for article (PubMed ID: 19010710)
21. Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
LeWitt PA
Adv Neurol; 1993; 60():544-7. PubMed ID: 8420188
[No Abstract] [Full Text] [Related]
22. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
Brashear A; Butler IJ; Hyland K; Farlow MR; Dobyns WB
Ann Neurol; 1998 Apr; 43(4):521-6. PubMed ID: 9546335
[TBL] [Abstract][Full Text] [Related]
23. Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury.
Wagner AK; Ren D; Conley YP; Ma X; Kerr ME; Zafonte RD; Puccio AM; Marion DW; Dixon CE
J Neurosurg; 2007 Apr; 106(4):538-47. PubMed ID: 17432702
[TBL] [Abstract][Full Text] [Related]
24. CSF homovanillic acid: an index of dopaminergic activity.
Curzon G
Adv Neurol; 1975; 9():349-57. PubMed ID: 125031
[TBL] [Abstract][Full Text] [Related]
25. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D
Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520
[TBL] [Abstract][Full Text] [Related]
26. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in CSF biomarkers for Parkinson's disease.
LeWitt P
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S49-51. PubMed ID: 22166453
[TBL] [Abstract][Full Text] [Related]
28. Dyskinesia-induced postural instability in Parkinson's disease.
Armand S; Landis T; Sztajzel R; Burkhard PR
Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
[TBL] [Abstract][Full Text] [Related]
29. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion.
Davis KL; Faull KF; Hollister LE; Barchas JD; Berger PA
Psychopharmacology (Berl); 1981; 72(2):155-60. PubMed ID: 6782605
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of indices of central dopaminergic functions in man.
Bagdy G; Arató M; Baraczka K; Fekete MI
Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
[TBL] [Abstract][Full Text] [Related]
31. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
Frecska E; Perényi A; Bagdy G; Révai K
Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
[TBL] [Abstract][Full Text] [Related]
32. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
Goldstein DS; Holmes C; Lopez GJ; Wu T; Sharabi Y
Parkinsonism Relat Disord; 2018 May; 50():108-112. PubMed ID: 29475591
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.
Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S
Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685
[TBL] [Abstract][Full Text] [Related]
35. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
36. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
[TBL] [Abstract][Full Text] [Related]
37. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease.
Isobe C; Murata T; Sato C; Terayama Y
J Clin Neurosci; 2007 Apr; 14(4):340-3. PubMed ID: 16647853
[TBL] [Abstract][Full Text] [Related]
38. Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
Watson E; Wilk S
Psychopharmacologia; 1975 Apr; 42(1):57-6. PubMed ID: 1153623
[TBL] [Abstract][Full Text] [Related]
39. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
40. Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
Goldstein DS; Sullivan P; Holmes C; Lamotte G; Lenka A; Sharabi Y
J Neurochem; 2021 Jul; 158(2):554-568. PubMed ID: 33894018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
